openPR Logo
Press release

Rigel and Proteros renew X-ray protein crystallography collaboration

07-12-2011 10:42 AM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried, Germany, July 12, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that it has renewed its agreement with Rigel Pharmaceuticals, Inc. (Rigel) to provide structural biology services for a Rigel drug discovery program.

Under this agreement, Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts. Proteros will deploy its high throughput crystallography platform and proprietary technologies.

Proteros focuses on providing structure based drug discovery services and continues to invest in developing its service platform which consists of X-ray protein crystallography, kinetic and thermodynamic compound profiling and integrated lead discovery based on a novel compound and fragment library of over 30,000 novel target directed molecules.

Cony D’Cruz, CBO and President of Proteros (US) Inc. said: “This agreement continues the long-standing structural biology collaboration between the two companies. We are pleased to be supporting Rigel with its pioneering research efforts.”

About Rigel Pharmaceuticals, Inc.:
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets
that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor in phase 3 clinical trials for rheumatoid arthritis (w/AstraZeneca), and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

About Proteros biostructures GmbH:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

Proteros biostructures GmbH
Dr. Thomas Waldmann
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 - 0
Fax: +49 (0) 89 7007 61 - 15
Email: business@proteros.com
Website: www.proteros.com

Rigel Pharmaceuticals, Inc.
Mr. Raul R. Rodriguez
President and Chief Operating Officer
1180 Veterans Blvd.
South San Francisco, CA 94080, USA
Phone: + 1 650 624 1100
Fax: + 1 650 624 1101
Email: invrel@rigel.com
Website: www.rigel.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rigel and Proteros renew X-ray protein crystallography collaboration here

News-ID: 183118 • Views:

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 4 Releases


More Releases for Rigel

Electrosurgical Analyzer Market 2022 Insights: Fluke Biomedical, Rigel Medical, …
Electrosurgical Analyzer Market research report deals with many parameters in depth to satisfy the requirements of business or clients. Moreover, it also displays all the information including market definition, classifications, key developments, applications, and engagements along with the detailed actions of key players with respect to product launches, joint ventures, developments, mergers and acquisitions, and effects of the same in terms of sales, import, export, revenue and CAGR values. A
Rheumatology Therapeutics Market Expected to Expand at a Study by Key players: A …
Rheumatology Therapeutics Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Rheumatology Therapeutics Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive Rheumatology Therapeutics
Investigation announced for Long-Term Investors in shares of Rigel Pharmaceutica …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Rigel Pharmaceuticals, Inc. Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Rigel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders. San Francisco,
Investigation announced for Investors in Rigel Pharmaceuticals, Inc. (NASDAQ: RI …
Rigel Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Rigel Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false
Rigel Networks Is Now A Kentico Certified Silver Partner
9th July 2019, Vadodara, Gujarat — Rigel Networks, an End to End IT Service Provider Company, today announced it has entered a Silver Partnership with Kentico Software (https://www.kentico.com), the Web Content and Customer Experience Management Provider, to provide customers with conversion-oriented web development solutions. From catering IT Services, Blockchain, Staffing, and VoIP, Rigel Networks delivers innovative technology-based IT services and solutions to their global clients for diverse industries to meet their
Chronic immune thrombocytopenia treatment Market Growth, Share, Demand, Innovati …
The chronic immune thrombocytopenia treatment is the most important treatment for those patient which are suffering from bleeding problem, the blood clotting process get slow or did not occurs in patient due to which major health issue can affect the body. The process of blood clotting is controlled by platelets or thrombocytes, the deficiency of platelets or thrombocytes in blood affect the patient during surgery or any major or